<DOC>
	<DOC>NCT01070823</DOC>
	<brief_summary>The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and to determine changes in anti-JCV antibody status over time.</brief_summary>
	<brief_title>JC-Virus (JCV) Antibody Program</brief_title>
	<detailed_description>This study requires serum, plasma and urine collection at enrollment and every 6 months thereafter for up two years.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Relapsing multiple sclerosis (MS) patients interested in or considering beginning treatment with Tysabri® (natalizumab). Key Patients participating in any other Tysabri® (natalizumab) clinical trial or study sponsored by Biogen Idec or Elan may not participate in this study. NOTE: Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sample Collection</keyword>
	<keyword>JCV</keyword>
	<keyword>PML</keyword>
</DOC>